Riskpilot← Back to searchSign inGet full accessBLOSTRUPMOEN NORGE AS
ASActiveOrg 918399046Kolonivegen, 2072 DalWholesale of pharmaceutical and medical goods · NACE 4646Est. 201725 employees
Revenue 2024
NOK 33,7M
+9% vs 2023
EBITDA margin
16.2%
-3% vs 2023
Equity ratio
4.5%
Financial strength
Net profit 2024
NOK 2,1M
-18% vs 2023
| Revenue | NOK 33,7M | +9% |
| EBITDA | NOK 5,5M | -3% |
| Net profit | NOK 2,1M | -18% |
| Total assets | NOK 19M | +12% |
| Equity | NOK 866K | +11% |
| Employees | 25 | — |
Legal name
BLOSTRUPMOEN NORGE AS
Org number
918399046
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
19. januar 2017
Share capital
NOK 30 000
Employees
25 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Salg og utleie av hjertestartere og kursing innenfor førstehjelp, salg av produkter innenfor førstehjelp/legemidler.
Address
Kolonivegen, 2072 Dal
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 22 643 | 25 276 | 29 649 | 30 970 | 33 684 |
| Staff expenses | −10 937 | −13 660 | −15 403 | −15 991 | −18 480 |
| EBITDA | 5 761 | 4 290 | 5 762 | 5 622 | 5 471 |
| Depreciation & amort. | −2 443 | −2 774 | −3 466 | −2 370 | −2 752 |
| EBIT | 3 317 | 1 516 | 2 296 | 3 252 | 2 720 |
| Net financials | 33 | 63 | 318 | −23 | −74 |
| Profit before tax | 3 350 | 1 578 | 2 614 | 3 230 | 2 646 |
| Tax | 738 | 352 | 576 | 711 | 583 |
| Net profit | 2 613 | 1 227 | 2 038 | 2 519 | 2 063 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 17 100 | 16 132 | 17 675 | 17 060 | 19 045 |
| Equity | 985 | 985 | 417 | 780 | 866 |
| Long-term debt | 0 | 150 | 0 | 296 | 242 |
| Short-term debt | 16 115 | 14 998 | 17 258 | 15 984 | 17 937 |
| Total debt | 16 115 | 15 147 | 17 258 | 16 280 | 18 179 |
EBITDA margin
16.2%
This company
15.8%
Market median
+3% vs market
20202024
Equity ratio
4.5%
This company
38.2%
Market median
-88% vs market
20202024
Return on equity
238.3%
This company
18.4%
Market median
+1195% vs market
20202024
Net profit margin
6.1%
This company
8.1%
Market median
-25% vs market
20202024
Asset turnover
1.77×
This company
1.12×
Market median
+58% vs market
20202024
Debt / equity
21.00×
This company
0.62×
Market median
-3287% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SB Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Skogen Group As
BLOSTRUPMOEN NORGE AS Board members of BLOSTRUPMOEN NORGE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stian Botten Olsen | Chief Executive Officer | 0 companies |
| Lars Håkon Blostrupmoen | Chairman | 0 companies |
| Sigbjørn Olav Ringvold | Board of Directors | 0 companies |
| Hans Georg Selmer | Board of Directors | 0 companies |
| Gunn Marit Stenvoll | Board of Directors | 0 companies |